Ellen Gentile, APRN
Nurse Practitioner · West Monroe, LANPI 1740560762
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,884 of the $30,799 with a category attached, or 71.1%. AbbVie accounts for 76.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2021 at $20,412 and has fallen 90.6% since, to $1,918 in 2025. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $53.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Novo Nordisk$1K
- AstraZeneca$995
- Lilly USA, LLC$818
- Esperion Therapeutics, Inc.$576
- Bayer$397
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$21,88471%
- Food & beverage$8,78329%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,799 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 173 | $179,216 |
| EliquisApixaban | 101 | $110,620 |
| FarxigaDapagliflozin Propanediol | 105 | $104,293 |
| JanuviaSitagliptin Phosphate | 62 | $65,243 |
| JardianceEmpagliflozin | 45 | $46,489 |
| UbrelvyUbrogepant | 35 | $45,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $42,558 |
| OzempicSemaglutide | 33 | $34,402 |
| MyrbetriqMirabegron | 39 | $27,719 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $18,366 |
| XareltoRivaroxaban | 15 | $14,806 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $12,015 |
| LinzessLinaclotide | 12 | $11,109 |
| TrulancePlecanatide | 14 | $10,428 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $818 | $179,216173 claims |
| PfizerEliquis, Paxlovid | $342 | $111,967112 claims |
| AstraZenecaFarxiga | $995 | $104,293105 claims |
| MerckJanuvia | $42 | $65,24362 claims |
| AbbVieUbrelvy, Linzess | $23,605 | $57,08847 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $236 | $53,90959 claims |
| GSKTrelegy Ellipta | $161 | $42,55843 claims |
| Novo NordiskOzempic | $1,034 | $34,40233 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $27,71939 claims |
| Esperion Therapeutics, Inc.Nexlizet | $576 | $18,36619 claims |
| Johnson & JohnsonXarelto | $12 | $14,80615 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $131 | $10,42814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in West Monroe
- Rita ZuberWest Monroe$9K
- Roger RutledgeWest Monroe$8K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.